Healthcare Industry News: NPWT
News Release - June 7, 2010
Smith & Nephew Launches Clinical Hotline for Patients Using RENASYS(TM) Negative Pressure Wound Therapy SystemsHotline offers immediate patient access to product information 24 hours a day, seven days a week
ST. PETERSBURG, Fla., June 7 (Healthcare Sales & Marketing Network) -- The Advanced Wound Management Division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc (LSE: SN; NYSE: SNN) announced the launch of its Negative Pressure Wound Therapy (NPWT) clinical hotline for patients.
Previously available to clinicians, patients with a NPWT System from Smith & Nephew can now also dial 1-866-998-NPWT (6798) and speak directly to patient-dedicated support staff who can answer patient education and product questions about NPWT Systems from Smith & Nephew. The clinical hotline is open 24 hours a day, seven days a week, 365 days a year.
"We are proud to be the only company offering patients a live and fully staffed hotline for its NPWT systems. We believe that it's our corporate and social responsibility to ensure that everyone using our RENASYS systems – clinicians and patients alike – has complete access to product information at all times to assure the safe use of medical devices," said Patricia Burns, Sr. Director Clinical Affairs at Smith & Nephew.
"The Food and Drug Administration (FDA) mandates that patients have access to product information and training to assure the safe use of medical devices. We believe that taking it to the next level by making it immediately accessible is the best approach to supporting patients," said Ms. Burns.
"The clinical hotline is a component of our investment in a comprehensive program to support the patient receiving NPWT in the home and further support appropriate product utilization and patient education," she continued. "Every NPWT system from Smith & Nephew will have the hotline number on it for easy patient access and use."
In addition to the clinical hotline, Smith & Nephew NPWT customers and patients can visit www.myrenasys.com to access information on device functionality and instructional videos on application techniques.
"Smith & Nephew is committed to NPWT and our goal with resources such as the hotline and www.myrenasys.com is to enable the patient receiving NPWT to go home with confidence," Burns said.
For more information about Smith & Nephew, please go to www.smith-nephew.com.
About Smith & Nephew
Smith & Nephew is a global medical technology business with global leadership positions in Orthopedics; including Reconstruction, Trauma and Clinical Therapies; Sports Medicine; and Advanced Wound Management.
Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2009 were nearly $3.8 billion.
This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.
All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Source: Smith & Nephew
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsSmith & Nephew to expand Real Intelligence digital ecosystem and CORI(TM) Surgical System with total hip arthroplasty
Smith & Nephew launches new total ankle and total shoulder replacement technologies; showcases recently acquired Extremity Orthopaedics portfolio at AAOS
New data underscores material benefits of Smith & Nephew's OXINIUM(TM) DH Technology and OR3O(TM) Dual Mobility System for total hip arthroplasty versus Cobalt Chrome liners